TC BioPharm (Holdings) PLC ('TC BioPharm' or the 'Company') (NASDAQ: TCBP), a biotechnology company in the clinical stage, focusing on the development of allogeneic gamma-delta T cell therapies for cancer and other ailments, has announced the signing of a non-binding letter of intent as part of its M&A strategy to broaden its therapeutic platform and harness NK (natural killer) cells for treating solid tumors and other conditions.The target acquisition involves the proprietary manufacturing process of two allogeneic CAR-NK therapeutics.

TC BioPharm（Holdings）PLC（“TC BioPharm”或“公司”）（纳斯达克：TCBP）是一家处于临床阶段的生物技术公司，专注于开发针对癌症和其他疾病的同种异体γ-δT细胞疗法，已宣布签署一份不具约束力的意向书，作为其并购战略的一部分，以扩大其治疗平台并利用NK（自然杀伤）细胞治疗实体瘤和其他疾病。目标收购涉及两种同种异体CAR-NK治疗剂的专有制造过程。

TCB sees significant value in both therapies, viewing them as effective monotherapies and potential complements to TCB-008 in the future. These CAR platforms are initially aimed at treating solid tumors, encompassing CD-70 CAR NK technology and HER2 CAR-NK technology. TCB anticipates substantial synergies from this potential acquisition, both in terms of clinical therapy by combining TCB-008 with CAR-NK assets and in leveraging TCB's existing expertise and workforce to enhance and refine the manufacturing process while incorporating additional CAR expertise to advance multiple platforms.There is compelling evidence supporting the synergistic roles of gamma delta T-cells and NK cells in the immune response against various diseases.

TCB认为这两种疗法都具有重要价值，将其视为有效的单一疗法和未来对TCB-008的潜在补充。这些CAR平台最初旨在治疗实体瘤，包括CD-70 CAR-NK技术和HER2 CAR-NK技术。TCB预计这一潜在收购将产生巨大的协同效应，无论是在临床治疗方面，通过将TCB-008与CAR-NK资产相结合，还是在利用TCB现有的专业知识和劳动力来增强和改进制造过程，同时结合额外的CAR专业知识来推进多个平台。有令人信服的证据支持γδT细胞和NK细胞在针对各种疾病的免疫应答中的协同作用。

The advantage of NK cells lies in their ability to recognize cancer cells without genetic engineering, enabling expedited treatment for patients.According to the terms of the LOI, TC BioPharm has been granted exclusivity while both parties collaborate in good faith on drafting a definitive agreement.

NK细胞的优势在于它们能够在没有基因工程的情况下识别癌细胞，从而能够快速治疗患者。根据意向书的条款，TC BioPharm已被授予排他性，而双方在起草最终协议时真诚合作。

However, there is no guarantee that a definitive agreement will be reached or that the proposed transaction will be completed as currently envisaged. The approval of TC BioPharm's Board of Directors is pending. Upo.

然而，不能保证会达成最终协议，也不能保证拟议的交易会按照目前的设想完成。TC BioPharm董事会的批准正在等待中。万国邮联。